Evidence map›Paper›PMID 35664003›Full record

ArticleFrontiers in immunology2022

RGMa Participates in the Blood-Brain Barrier Dysfunction Through BMP/BMPR/YAP Signaling in Multiple Sclerosis.

Lei Zhang, Shi Tang, Yue Ma, Junhang Liu, Philippe Monnier, Hang Li, Rongrong Zhang, Gang Yu, Mengjie Zhang, Yongmei Li and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Lei ZhangDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Shi TangDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yue MaDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Junhang LiuDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Philippe MonnierDonald K. Johnson Eye Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Hang LiDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Rongrong ZhangDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Gang YuDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Mengjie ZhangDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yongmei LiDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jinzhou FengDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xinyue QinDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
First Affiliated Hospital of Chongqing Medical University · CNChongqing Medical University · CNUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The infiltration of inflammatory cells into the central nervous system (CNS) through the dysfunctional blood-brain barrier (BBB) was critical in the early stages of MS. However, the mechanisms underlying BBB dysfunction remain unknown. Repulsive guidance molecule-a (RGMa) is involved in the pathogenesis of multiple sclerosis (MS), but its role needs to be further explored. This study aimed to evaluate whether RMGa regulates BBB permeability in endothelial cells and MS, and if so, what mechanism may be involved. We created an experimental autoimmune encephalomyelitis (EAE) model in C57BL/6 mice and a human brain microvascular endothelial cell (HBMEC) culture. The permeability of the BBB is measured in response to various interventions. Our results showed that RGMa is expressed in the endothelial cells in HBMECs and EAE mice. RGMa and its signaling counterpart, bone morphogenetic protein 2 (BMP2)/bone morphogenetic protein receptor type II (BMPRII), were gradually increased as the disease progressed. Moreover, as EAE progressed and the BBB was disrupted, the downstream effector, yes-associated protein (YAP), as well as the tight junctional proteins zonula occludens 1 (ZO-1) and claudin-5, decreased significantly. The permeability assay revealed that lentivirus-induced RGMa overexpression in HBMECs caused a significant breakdown of the BBB, whereas RGMa knockdown significantly strengthens the integrity of the BBB. Furthermore, specifically activating BMPR II or inhibiting YAP based on RGMa knockdown results in a significant decrease of ZO-1 and claudin-5

Indexed as

Encephalomyelitis, Autoimmune, ExperimentalMultiple SclerosisAnimalsBlood-Brain BarrierClaudin-5Endothelial CellsGPI-Linked ProteinsHumansMiceMice, Inbred C57BLNerve Tissue ProteinsClaudin-5GPI-Linked ProteinsNerve Tissue ProteinsRgma protein, mouseblood–brain barrierbone morphogenetic proteinmultiple sclerosisrepulsive guidance molecule-ayes-associated protein

Identifiers

PMID35664003
PMCPMC9159795
OpenAlexW4280579981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.